Tasquinimod

Catalog No.C12819 Batch:C1281903

Product Datasheet

Technical Data

Formula	$C_{20}H_{17}F_3N_2O_4$					
Molecular Weight	406.36	**CAS No.**	254964-60-8			
Solubility (25°C)*	In vitro	DMSO	81 mg/mL (199.33 mM)			
		Ethanol	10 mg/mL (24.6 mM)			
		Water	Insoluble			
	In vivo (Add solvents to the product individually and in order)	Oral Administration	Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
		Injection	Clear solution	5%DMSO $\xrightarrow{1}$ Corn oil Validated by Capsid Bio labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (2.46mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Capsid Bio tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped at 2-8°C for storage purposes.)

Preparing Stock Solutions

Biological Activity

Description	Tasquinimod (ABR-215050) is an orally active **antiangiogenic** agent by allosterically inhibiting **HDAC4** signalling. Phase 3.
Targets	HDAC4 [1]
In vitro	Tasquinimod inhibits tumor angiogenesis by allosteric inhibition of HDAC4/N-CoR/HDAC3 dependent deacetylation of HIF-1α. [1] This compound also targets infiltrating myeloid cells, and modulates local tumour immunity by blocking the interaction between S100A9 and its ligands receptor of advanced glycation end products and Toll-like receptor 4. [3]
In vivo	This compound (30 mg/kg/d p.o.) shows anti-angiogenic activity and thus causes tumor growth inhibition in mice bearing human and rodent prostate cancer models. [2]

Protocol (from reference)

Cell Assay:[4]

- **Cell lines**
  LNCaP19 cells
- **Concentrations**
  10 μM
- **Incubation Time**
  72 h
- **Method**
  Cells were treated with indicated concentration of this compound for 72 h.

Animal Study:[2]

- **Animal Models**
  Mice bearing PC-82 , CWR-22Rv1, LAPC-4, or LNCaP prostate cancer xenografts.
- **Dosages**
  ~30 mg/kg/d
- **Administration**
  p.o.

References

https://pubmed.ncbi.nlm.nih.gov/23149916/ https://pubmed.ncbi.nlm.nih.gov/16955399/ https://pubmed.ncbi.nlm.nih.gov/24162378/

+ Expand

RETURN POLICY

Capsid Bio's Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING & STORAGE

Capsid Bio products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Capsid Bio Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Capsid Bio products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

EU Headquarters
Gajeva ulica 28, HR-10000 Zagreb, Croatia

US Headquarters
12222 Merit Dr STE 130 Dallas, Texas, 75251

UK Headquarters
121 ABILITY HOUSE, BROOKER ROAD, EN9 1JH, ESSEX

Orders: Sales@capsidbio.com
Enquiries: info@capsidbio.com
www.capsidbio.com